BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a hold rating in a research note released on Wednesday,Zacks reports.

Several other equities research analysts also recently commented on BLSM. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 target price for the company. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set a “buy” rating and a $35.00 price objective for the company. Leerink Partners initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $36.00 price objective on the stock. Guggenheim initiated coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $32.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

BlossomHill Therapeutics Trading Up 3.3%

Shares of BLSM stock opened at $20.02 on Wednesday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $20.61.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc acquired 625,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This trade represents a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Carl Gordon bought 625,000 shares of the stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 1,573,900 shares of company stock worth $25,181,900 over the last three months.

Trending Headlines about BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $36 price target, while HC Wainwright began coverage with a Buy rating and a $35 target. These targets imply substantial potential appreciation if the company executes successfully. BlossomHill Therapeutics Research Coverage Started at Leerink Partners BlossomHill Therapeutics Research Coverage Started at HC Wainwright
• Positive Sentiment: Guggenheim also initiated coverage with a Buy rating and a $30 price target. The cluster of bullish initiations provides broader sell-side validation for BLSM. BlossomHill Therapeutics Research Coverage Started at Guggenheim
• Positive Sentiment: Additional coverage was initiated by JPMorgan Chase and Lifesci Capital, increasing institutional visibility for the clinical-stage cancer drug developer.
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could give investors more information about its small-molecule oncology pipeline and development progress. BlossomHill Therapeutics Conference Presentations
• Neutral Sentiment: HC Wainwright continues to forecast losses, including fiscal 2026 EPS of approximately ($3.71) and fiscal 2027 EPS of ($2.99). However, its estimates improve through 2027, supporting the firm’s Buy rating and $35 price objective.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.